CIK 0001175680 · Non-accelerated filer<br>Smaller reporting company
CytoDyn Inc.
Sign in to watch- Ticker
- CYDY
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- May 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753056237
- Phone
- 360-980-8524
- Business address
- 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660
- Former names
- CYTODYN INC, REXRAY CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-20 | Hoffman Robert E. Chief Executive Officer | Grant or award · Non-qualified stock option (right to buy) | +2,500,000 | 2,500,000 | ||
| 2026-03-20 | Urbach Tanya Durkee Director | Grant or award · Non-qualified stock option (right to buy) | +574,385 | 574,385 | ||
| 2026-03-20 | SIMES STEPHEN M Director | Grant or award · Non-qualified stock option (right to buy) | +574,385 | 574,385 | ||
| 2026-03-20 | Ndhlovu Lishomwa C Director | Grant or award · Non-qualified stock option (right to buy) | +574,385 | 574,385 | ||
| 2026-03-20 | Lalezari Jacob P Chief Executive Officer | Grant or award · Non-qualified stock option (right to buy) | +4,874,691 | 4,874,691 | ||
| 2026-03-20 | Hoffman Robert E. Chief Financial Officer | Grant or award · Non-qualified stock option (right to buy) | +4,874,691 | 4,874,691 | ||
| 2026-03-20 | Dunlap Ryan Director | Grant or award · Non-qualified stock option (right to buy) | +574,385 | 574,385 | ||
| 2026-03-20 | Brunke Karen J Director | Grant or award · Non-qualified stock option (right to buy) | +574,385 | 574,385 | ||
| 2026-03-20 | Blok Tyler Chief Legal Officer | Grant or award · Non-qualified stock option (right to buy) | +3,249,794 | 3,249,794 | ||
| 2025-05-15 | Hoffman Robert E. Chief Financial Officer | Grant or award · Non-qualified stock option (right to buy) | +1,000,000 | 1,000,000 | ||
| 2024-10-28 | Urbach Tanya Durkee Director | Grant or award · Non-qualified stock option (right to buy) | +800,000 | 800,000 | ||
| 2024-10-28 | SIMES STEPHEN M Director | Grant or award · Non-qualified stock option (right to buy) | +800,000 | 800,000 | ||
| 2024-10-28 | Ndhlovu Lishomwa C Director | Grant or award · Non-qualified stock option (right to buy) | +800,000 | 800,000 | ||
| 2024-10-28 | Lalezari Jacob P Chief Executive Officer | Grant or award · Non-qualified stock option (right to buy) | +3,000,000 | 3,000,000 | ||
| 2024-10-28 | Dunlap Ryan Director | Grant or award · Non-qualified stock option (right to buy) | +800,000 | 800,000 | ||
| 2024-10-28 | Brunke Karen J Director | Grant or award · Non-qualified stock option (right to buy) | +800,000 | 800,000 | ||
| 2024-10-28 | Blok Tyler Chief Legal Officer | Grant or award · Non-qualified stock option (right to buy) | +1,250,000 | 1,250,000 | ||
| 2024-03-07 | Lalezari Jacob P Chief Executive Officer | Grant or award · Non-qualified stock option (right to buy) | +3,000,000 | 3,000,000 | ||
| 2024-01-03 | Migliarese Antonio CFO | Returned to the company · Non-qualified stock option (right to buy) | −50,000 | 0 | ||
| 2024-01-03 | Migliarese Antonio CFO | Returned to the company · Non-qualified stock option (right to buy) | −50,000 | 0 |
Page 1 of 33 · 652 trades